Scorpius Holdings Secures Major Deal With Leading Biotech Firm, Paving Way for Future GMP Manufacturing

Scorpius Holdings, Inc., an integrated contract development and manufacturing organisation (CDMO), has announced plans to offer bioanalytical services to a publicly traded clinical-stage immuno-oncology firm. This partnership opens the doors to many new possibilities; Scorpius expects its portfolio to grow with new analytical services and further GMP manufacturing opportunities following this initial phase. The award highlights Scorpius's ability to provide critical bioanalytical and process development services, establishing it as a most valued partner in biologics manufacturing.

Jeff Wolf, CEO of Scorpius, commented, "This important contract is a clear validation of Scorpius’ comprehensive capabilities, which include advanced bioanalytical services. Our state-of-the-art bioanalytical and process development facilities enable us to offer an integrated solution that meets the diverse needs of biologics manufacturers. We are excited by the potential to develop this partnership further and to offer ongoing bioanalytical support and future GMP manufacturing services to help advance this client’s clinical programs.”